Market open
BioVie/$BIVI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BioVie
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
Ticker
$BIVI
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
14
ISIN
US09074F4054
Website
BioVie Metrics
BasicAdvanced
$23M
-
-$3.13
1.03
-
Price and volume
Market cap
$23M
Beta
1.03
52-week high
$5.08
52-week low
$0.62
Average daily volume
600K
Financial strength
Current ratio
16.941
Quick ratio
16.752
Long term debt to equity
1.316
Total debt to equity
1.597
Interest coverage (TTM)
-17.20%
Management effectiveness
Return on assets (TTM)
-63.41%
Return on equity (TTM)
-154.54%
Valuation
Price to book
0.95
Price to tangible book (TTM)
0.97
Price to free cash flow (TTM)
-0.456
Growth
Earnings per share change (TTM)
-73.61%
3-year earnings per share growth (CAGR)
-65.21%
What the Analysts think about BioVie
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for BioVie stock.
BioVie Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
BioVie Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
BioVie News
AllArticlesVideos
BIOVIE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioVie Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
GlobeNewsWire·1 week ago
BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for BioVie stock?
BioVie (BIVI) has a market cap of $23M as of May 09, 2025.
What is the P/E ratio for BioVie stock?
The price to earnings (P/E) ratio for BioVie (BIVI) stock is 0 as of May 09, 2025.
Does BioVie stock pay dividends?
No, BioVie (BIVI) stock does not pay dividends to its shareholders as of May 09, 2025.
When is the next BioVie dividend payment date?
BioVie (BIVI) stock does not pay dividends to its shareholders.
What is the beta indicator for BioVie?
BioVie (BIVI) has a beta rating of 1.03. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.